Market capitalization | $9.16m |
Enterprise Value | $103.89m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 451.70 |
P/S ratio (TTM) P/S ratio | 39.83 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 0.00% |
Revenue (TTM) Revenue | $230.00k |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
2 Analysts have issued a Onconova Therapeutics Inc. forecast:
2 Analysts have issued a Onconova Therapeutics Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.23 0.23 |
0%
0%
|
|
Gross Profit | 0.21 0.21 |
0%
0%
|
|
EBITDA | -21 -21 |
7%
7%
|
EBIT (Operating Income) EBIT | -21 -21 |
7%
7%
|
Net Profit | -137 -137 |
558%
558%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.
Head office | United States |
CEO | Werner Cautreels |
Employees | 17 |
Founded | 1998 |
Website | www.trawspharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.